Doctor Details

Dr. Sumant Gupta
  • Name
    Dr. Sumant Gupta
  • Address
    Sarvodaya Hospital Research Centre Sector 8, Sarvodaya Medicentre
  • Designation
    Senior Consultant - Medical Oncology & BMT
    HOD - Sarvodaya Cancer Institute
  • Department

    Sarvodaya Cancer Institute

Dr. Sumant Gupta

Dr. Sumant Gupta has been trained from prestigious Cancer Institute (WIA) Adyar, Chennai & All India Institute of Medical Sciences (AIIMS).  His Special nterests include Haemetological Malignancies & Bone Marrow Transplant. He was instrumental in performing the first Bone Marrow Transplant in Faridabad. He was the winner of TYSA Young Scholar Award (Medical Oncologist) for the Best DM - Oncology fellow (2015). He has more than 10 National & International papers in his credit. He is currently the executive committee member of Indian Society of Oncology & Breast Cancer Foundation-India & Founder Executive Secretary of National Cancer Society.


  • Adult Medical Oncology and Hemato-oncology
  • Pediatric Hemato-Oncology
  • Bone Marrow Transplantation


  • DM (Medical Oncology) from Cancer Institute (WIA) Adyar, Chennai
  • MD (Internal Medicine) from Chaudhary Charan Singh University, Meerut (UP)
  • MBBS from SSMC, Tumkur, Rajiv Gandhi University of Health Sciences Karnataka, India


  • Associate Consultant Medical Oncology at Batra Hospital, New Delhi
  • Senior Registrar at Department of Medical Oncology at All India Institute of Medical sciences, New Delhi
  • DM (Medical Oncology and Pediatric Hemato-oncology) at Cancer Institute (WIA) Chennai


  • TYSA Young Scholar Award for the Best DM – Medical Oncology, 2015
  • Winner of TYACON Quiz at the Annual conference of Teen and young oncology 2013 at Delhi.

Other Information

Research and Publications :

  • Molecular Biology of Lung Cancer—A Review- Indian Journal of Surgical Oncology, Vol.4 No 2, 2013
  • Neutrophil response kinetics after G-CSF and Pef G-CSF usage post chemotherapy, Journal of Clinical Oncology Vol.26 No. 15S abst 20708, 2008
  • Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal hR3 (nimotuzumab) with chemotherapy- A study of toxicity profile and tolerance, journel of clinical Oncology vol.25.No 18S, abstract 14151, 2007
  • LYMPHOBLASTIC LEUKEMIA:A single centre experience with BFM-95 PROTOCOL with manuscript number ijmpo_227-14 is acceptable for publication in the journel